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Interrupting blood flow to a heart (ischemia) for several
minutes followed by several minutes of restored flow
renders it very resistant to cell death from a subsequent
much more prolonged ischemic episode. This phenom-
ena, termed ischemic preconditioning, is the result of a
complex signal transduction pathway which ultimately
prevents formation of lethal mitochondrial permeability
transition pores when blood flow is restored. In mapping
this pathway we found that NOS was in the pathway [1]
and proposed that it was involved in opening ATP-sensi-
tive potassium channels (KATP) in the mitochondrial inner
membrane. Those channels play a key role in precondi-
tioning's mechanism. Incubating isolated heart mito-
chondria in cGMP + PKG + ATP opened the channel as
indicated by mitochondrial swelling [2]. To test this
hypothesis further the cGMP analog 8-CPT-cGMP (10
μM) was infused for 30 min starting 5 min prior to the end
of 30 min of regional ischemia in an isolated rabbit heart
[3]. It greatly attenuated the resulting infarction by an
amount similar to that seen with preconditioning (infarct
size approximately 50% of that in untreated hearts). 8-
CPT's protection could be blocked by the KATP blocker 5
hydroxydecanoate confirming its position in the pathway.
Because there is a medical need for an intervention that
prevents myocardial infarction when given at reperfusion
we looked for a method of raising cGMP that would be
clinically feasible. We gave the direct guanylyl cyclase acti-
vator BAY 58-2667 (cinaciguat) to open-chest rabbits at
53 μg/kg bolus just prior to reperfusion followed by a 60
min 1.25 μg/min infusion. It reduced infarct size from
40.6% of the ischemic zone to only 16.0%. In another
experiment we tested Vardenafil infusion of 140 μg/kg/h
starting 5 min before coronary occlusion in the open-
chest rabbit. It also greatly protected the hearts against inf-
arction. Because it is controversial as to whether heart
muscle expresses PDE 5, we transfected isolated rabbit
ventricular myocytes with CNG channels selective for
cGMP. In the resting cells cGMP as monitored with patch
clamping was near zero and did not increase when they
were exposed to 1 μM vardenafil. However, when cGMP
was first increased with 1 μM BAY 58-2667 addition of
vardenafil greatly increased the cGMP-dependent mem-
brane current indicating that a vardenafil-sensitive PDE
was present which is presumed to be PDE5. We conclude
that raising cGMP in the reperfused heart is an effective
anti-infarct strategy.
References
1. Oldenburg O, Qin Q, Krieg T, Yang XM, Philipp S, Critz SD, Cohen
MV, Downey JM: Bradykinin induces mitochondrial ROS gen-
eration via NO, cGMP, PKG, and mitoKATP channel opening
and leads to cardioprotection.  Am J Physiol 2004,
286:H468-H476.
2. Costa ADT, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen
MV, Critz SD: Protein kinase G transmits the cardioprotective
signal from cytosol to mitochondria.  Circ Res 2005, 97:329-336.
3. Kuno A, Solenkova NV, Solodushko V, Dost T, Liu Y, Yang XM,
Cohen MV, Downey JM: Infarct limitation by a protein kinase G
activator at reperfusion in rabbit hearts is dependent on sen-
sitizing the heart to A2b agonists by protein kinase C.  Am J
Physiol Heart Circ Physiol 2008, 295:H1288-H1295.
from 4th International Conference of cGMP Generators, Effectors and Therapeutic Implications
Regensburg, Germany. 19–21 June 2009
Published: 11 August 2009
BMC Pharmacology 2009, 9(Suppl 1):S9 doi:10.1186/1471-2210-9-S1-S9
<supplement> <title> <p>4th International Conference of cGMP Generators, Effectors and Therapeutic Implications</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1471-2210-9-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2210-9-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.biomedcentral.com/1471-2210/9/S1/S9
© 2009 Downey et al; licensee BioMed Central Ltd. 